4D Molecular Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year Five
4D Molecular Therapeutics, Inc. (FDMT) had Lessee, Operating Lease, Liability, to be Paid, Year Five of $5.46 million as of 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive · last filed 2026-03-18
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $5.46M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $5.67M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $2.89M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $2.81M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Five |
|---|---|
| 2025-12-31 | $5.46M 10-K · filed 2026-03-18 |
| 2024-12-31 | $5.67M 10-K · filed 2025-02-28 |
| 2023-12-31 | $2.89M 10-K · filed 2024-02-29 |
| 2022-12-31 | $2.81M 10-K · filed 2023-03-15 |
| 2021-12-31 | $3.13M 10-K · filed 2022-03-28 |
| 2020-12-31 | $3.26M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |